Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan

Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following...

Full description

Saved in:
Bibliographic Details
Published inClinical nuclear medicine Vol. 43; no. 1; p. 23
Main Authors Gill, Harkanwar S, Tade, Funmilayo, Greenwald, David Theodore, Yonover, Paul M, Savir-Baruch, Bital
Format Journal Article
LanguageEnglish
Published United States 01.01.2018
Subjects
Aged
Biological Transport
Breast Neoplasms, Male - diagnostic imaging
Breast Neoplasms, Male - metabolism
Carboxylic Acids - metabolism
Cyclobutanes - metabolism
Humans
Incidental Findings
Male
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Recurrence
Online AccessGet more information

Cover

More Information
Summary:Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. We present a rare case of a 77-year-old man with suspected recurrent prostate cancer with an incidental finding of advanced-stage breast cancer showing different degrees of F-fluciclovine uptake.
ISSN:1536-0229
DOI:10.1097/RLU.0000000000001893